---
title: "Telix climbs for second trading day following Pixclara approval"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299076068.md"
description: "Telix Pharmaceuticals shares rose ~11% on Tuesday, continuing a two-day gain following US FDA approval of Pixclara, the first FET-PET imaging agent for glioma. CEO Christian Behrenbruch highlighted Pixclara's potential as a platform and noted complementary therapeutic progress with TLX-101 in phase 3 trials for glioblastoma multiforme."
datetime: "2026-09-15T16:16:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299076068.md)
  - [en](https://longbridge.com/en/news/299076068.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299076068.md)
generator: "portal-rs"
---

# Telix climbs for second trading day following Pixclara approval


### Related Stocks

- [TLX.US](https://longbridge.com/en/quote/TLX.US.md)
- [TLX.AU](https://longbridge.com/en/quote/TLX.AU.md)

## Related News & Research

- [Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging](https://longbridge.com/en/news/300495723.md)
- [Telix wins FDA Fast Track for BiPASS pre-biopsy prostate cancer imaging study](https://longbridge.com/en/news/300489191.md)
- [Canaccord Genuity Keeps Their Buy Rating on Telix Pharmaceuticals (TLPPF)](https://longbridge.com/en/news/300886940.md)
- [IBA agrees to distribute Telix unit ARTMS’ QUANTM solid-target cyclotron technology worldwide](https://longbridge.com/en/news/300644879.md)
- [FDA approves Telix brain cancer imaging drug Pixclara for glioma PET scans](https://longbridge.com/en/news/298841235.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**